Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00374855
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 2
Start date September 2006
Completion date November 2006

See also
  Status Clinical Trial Phase
Completed NCT01331486 - Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract Phase 1
Not yet recruiting NCT04908917 - Reducing Air Pollution to Lower Blood Pressure N/A
Completed NCT03714776 - A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure Phase 2